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Primary prevention of cardiovascular disease (CVD) requires adequate control of hyperten-
sion and diabetes. We designed and implemented pharmaceutical and healthy lifestyle
interventions for patients with diabetes and/or hypertension in rural primary care, and
assessed their effectiveness at reducing severe CVD events.
Methods and findings
We used a pragmatic, parallel group, 2-arm, controlled, superiority, cluster trial design. We
randomised 67 township hospitals in Zhejiang Province, China, to intervention (34) or con-
trol (33). A total of 31,326 participants were recruited, with 15,380 in the intervention arm
and 15,946 in the control arm. Participants had no known CVD and were either patients with
hypertension and a 10-year CVD risk of 20% or higher, or patients with type 2 diabetes
regardless of their CVD risk. The intervention included prescription of a standardised pack-
age of medicines, individual advice on lifestyle change, and adherence support. Control was
usual hypertension and diabetes care. In both arms, as usual in China, most outpatient drug
costs were out of pocket. The primary outcome was severe CVD events, including coronary
heart disease and stroke, during 36 months of follow-upAU : Ichangedafter36monthsofinterventiontoduring36monthsoffollow   up:Ifthisisnotcorrect; pleaseedit:, as re orded by the CVD surveil-
lance system. The study was implemented between December 2013 and May 2017. A total
of 13,385 (87%) and 14,745 (92%) participated in the intervention and control arms, respec-
tively. Their mean age was 64 years, 51% were women, and 90% were farmers. Of all par-
ticipants, 64% were diagnosed with hypertension with or without diabetes, and 36% were
diagnosed with diabetes only. All township hospitals and participants completed the 36-







Citation: Wei X, Zhang Z, Chong MKC, Hicks JP,
Gong W, Zou G, et al. (2021) Evaluation of a
package of risk-based pharmaceutical and lifestyle
interventions in patients with hypertension and/or
diabetes in rural China: A pragmatic cluster
randomised controlled trial. PLoS Med 18(7):
e1003694. https://doi.org/10.1371/journal.
pmed.1003694
Academic Editor: David Peiris, The George
Institute for Global Health, UNSW Sydney,
AUSTRALIA
Received: October 14, 2020
Accepted: June 13, 2021
Published: July 1, 2021
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pmed.1003694
Copyright: © 2021 Wei et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in
any medium, provided the original author and
source are credited.
month follow-up. At 36 months, there were 762 and 874 severe CVD events in the interven-
tion and control arms, respectively, yielding a non-significant effect on CVD incidence rate
(1.92 and 2.01 per 100 person-years, respectively; crude incidence rate ratio = 0.90 [95%
CI: 0.74, 1.08; P = 0.259]). We observed significant, but small, differencesAU : HereandintheAuthorsummary; Ichangedreductionstodifferences:Ifthisdoesnotcaptureyourmeaning; pleaseedit:in the change
from baseline to follow-up for systolic blood pressure (−1.44 mm Hg [95% CI: −2.26, −0.62;
P < 0.001]) and diastolic blood pressure (−1.29 mm Hg [95% CI: −1.77, −0.80; P < 0.001]) in
the intervention arm compared to the control arm. Self-reported adherence to recom-
mended medicines was significantly higher in the intervention arm compared with the con-
trol arm at 36 months. No safety concerns were identified. Main study limitations include all
participants being informed about their high CVD risk at baseline, non-blinding of partici-
pants, and the relatively short follow-up period available for judging potential changes in
rates of CVD events.
Conclusions
The comprehensive package of pharmaceutical and healthy lifestyle interventions did not
reduce severe CVD events over 36 months. Improving health system factors such as uni-





Why was this study done?
• Pharmaceutical interventions AU : Pleasecheckthattheeditstothesentence}Pharmaceuticalinterventions:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:have be n shown to reduce cardiovascular disease (CVD)
events, but the evidence has limited policy implications as medicines in trials have been
typically been provided free of charge.
• Four previous trials examining CVD-risk-based management treatments in high-
income countries were focused on healthy lifestyle interventions and did not identify
any clear effects on CVD events. Two previous trials in low- and middle-income coun-
tries implemented both pharmaceutical and lifestyle interventions, but they were not
designed to examine impacts on CVD events.
What did the researchers do and find?
• We conducted a cluster randomised controlled trial in rural China among 31,326
patients with (1) hypertension who had a CVD risk of 20% or higher or (2) diabetes,
and followed participants up for 36 months. Interventions included prescription of a
standardised package of medicines, individual advice on lifestyle change, and adherence
support provided by a team led by family doctors. We compared this to usual existing
care.
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• The study found that our comprehensive pharmaceutical and lifestyle interventions did
not reduce severe CVD events.
• We observed significant, but small, differences in the change from baseline to follow-up
of systolic blood pressure (−1.44 mm Hg) and diastolic blood pressure (−1.29 mm Hg)
in the intervention arm compared to the control arm. Self-reported adherence to rec-
ommended medicines was significantly higher in the intervention arm compared with
the control arm at 36 months.
• In the process evaluation, we identified that the unaffordability of the medications,
caused by lack of health insurance coverage and the non-availability of cheaper generic
medicine, appeared to discourage patients from taking recommended medicines.
What do these findings mean?
• Comprehensive pharmaceutical and lifestyle interventions were feasible and effective in
improving medicine uptake and reducing blood pressure, but not in achieving a reduc-
tion in severe CVD events, when implemented in a setting where the costs of essential
medicines were insufficiently covered.
• This study highlights the importance of improving universal health coverage as a pre-
requisite for effective CVD prevention programmes in primary care in similar settings.
Introduction
Cardiovascular disease (CVD) is the world’s leading cause of mortality, representing 31% of all
global deaths in 2016 [1]. The United Nations Sustainable Development Goal (SDG) 3 calls for
a one-third reduction in CVD deaths by 2030. However, this goal will not be achieved without
progressive prevention activities that include adequate control of blood pressure, glucose, and
lipid levels, as well as smoking cessation, and reducing salt, alcohol, sugar, and trans fat intake
[2]. Primary care provides the best setting for these solutions because hypertension and diabe-
tes, the 2 most common risk factors for CVD, are managed by family doctors, who can provide
continuous, coordinated, and comprehensive care. However, hypertension and diabetes are
often treated and managed separately, as reflected in the frequent existence of separate guide-
lines and programmes. In addition, the 2 diseases are both typically inadequately controlled in
low- and middle-income countries (LMICs) compared to high-income countries (HICs).
Recent multi-country studies reported that only 10% of patients with hypertension had con-
trolled hypertension in LMICs, compared to 50% in HICs [3,4].
To achieve SDG 3, a comprehensive treatment approach consisting of both pharmaceutical
and lifestyle strategies is urgently needed in LMICs. The ability of recommended antihyperten-
sive medicines, aspirin, and statins to prevent CVD events has been well documented in trials
[1]. Recommended AU : Pleasecheckthattheeditstothesentence}Recommendedpharmaceuticaltherapy:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:pharmaceutical ther py, often in th form of a co bine polypill, can
reduce CVD risk by 50%–60% in the long term [5], but the effects are often more modest, as
shown in the PolyIran trial [6] (34% reduction in hazard ratio for major CVD events [95% CI:
20%, 45%] over 60 months). Meta-analyses of healthy lifestyle interventions, including those
targeting weight loss, alcohol reduction, and smoking cessation, have shown moderate
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improvements in biomarkers of CVD risk factors, such as blood pressure, body mass index
(BMI), and total serum cholesterol [7]. Thus, combined pharmaceutical and lifestyle interven-
tions could be more beneficial to patients at high risk of CVD. Several trials have reported pos-
itive effects of combined pharmaceutical and lifestyle interventions, including reduced patient
CVD risks, blood pressure, and lipid profiles, but none demonstrated reductions in CVD
events [8–11]. The strategy of risk-based pharmaceutical and lifestyle interventions has been
suggested in national clinical guidelines; however, the policy question of whether this strategy
has any impact to achieve SDG 3 remains unanswered due to insufficient evidence [12].
Our previous study identified health system barriers to sustainable CVD risk management,
such as insufficient knowledge amongst family doctors, use of ineffective medicines, and lack
of treatment support [13]. China’s recent health reforms provided an opportunity for better
control of non-communicable diseases as they strengthened primary care capacities and
improved hypertension and diabetes management [14]. Based on this, we designed and imple-
mented a comprehensive package of pharmaceutical and healthy lifestyle interventions embed-
ded into routine primary care practice for primary prevention of CVD among patients with
diabetes and hypertension. We have previously reported feasibility results from our pilot study
[15], the trial protocol [16], and the effect on pharmaceutical management [17]. Here we
report the evaluation of relevant interventions against the trial’s primary and secondary out-
comes during 36 months of follow-up.
Methods
Study design
Our study is a pragmatic, parallel group, 2-arm, cluster randomised, controlled, superiority
trial. It aims to assess the effectiveness of a package of comprehensive pharmaceutical and
healthy lifestyle interventions targeting primary prevention of CVD among patients with high
CVD risk in rural China. We conducted the research in township hospitals, which are rural pri-
mary care facilities. Township hospitals and their catchment populations are the clusters of the
trial. Details of the trial design and analysis plan have been published elsewhere [16]. In brief,
we selected all township hospitals, except 1 that served as the pilot site, in 3 counties in Zhejiang
Province. Cluster eligibility criteria included having electronic medical records covering the last
2 years for residents in these townships. This study was approved by the Ethics Review Board of
the University of Leeds, UK (reference HSLTLM/12/010) and the Ethics Committee of Zhejiang
Provincial Centre for Disease Control and Prevention, China (reference 18/06/2012). Written
informed consent was obtained from all participating individuals. We used the CONSORT clus-
ter trials checklist (S1 CONSORT Checklist) to help in reporting the study [18].
Participants
We recruited participants from township hospitals based on collected health records from all
residents in their catchment areas. Patients were considered eligible if they had the following
characteristics: (1) aged 50 to 74 years; (2) permanent residents in the township; (3) having
either hypertension with a 10-year CVD risk� 20% calculated using the Asian equation [19],
or type 2 diabetes (with or without hypertension); (4) free from any diagnosed mental diseases
or physical disabilities, any history of severe CVD events, or other diseases as defined in the
protocol [16]; (5) not currently hospitalised or living in a long-term care facility; (6) no serious
adverse effects to the recommended medicines, and (7) having a diastolic blood pressure� 60
mm Hg. After cluster randomisation, all potentially eligible participants were invited to visit
the township hospital, where family doctors explained the study, recruited patients, and
obtained their consent.
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Randomisation and masking
In December 2013, we randomised a total of 67 township hospitals, without stratification, to
the intervention and control arms in a 34:33 ratio, via an independent statistician using com-
puter-generated random numbers. All eligible consenting participants received either the
intervention or control treatment based on the treatment allocated to their township hospital.
Due to the nature of the interventions, health providers and patients could not be blinded, but
the analysis of the trial was blinded.
Procedures
In both arms patients had recurring booked consultations with their doctors at least quarterly.
All recommended medicines were available in township hospitals or pharmacies in both arms.
Patients purchased their medications from township hospitals or pharmacies using prescrip-
tions from their family doctors, and then reported their adherence to the prescriptions in the
next consultation.
In the control arm, usual care of hypertension and diabetes continued per existing practice.
No additional recommendations for pharmaceutical or healthy lifestyle modifications were
provided. The 2010 Chinese national hypertension [20] and diabetes [21] guidelines were
available, but they were often not referred to in primary care consultations because the guide-
lines contain large amounts of information for tertiary care [22]. Family doctors treated hyper-
tension and diabetes according to their own discretion and group practice. No specific
training regarding CVD risk management was provided. Healthy lifestyle change education
was given based on controlling either hypertension or diabetes, but compared to the interven-
tion arm this was not using a holistic approach to CVD risk reduction. Treatment adherence
support was not provided.
In the intervention arm, patients received prescriptions and healthy lifestyle education for
treatment of their existing medical conditions and CVD prevention. All patients with hyper-
tension, or hypertension and diabetes, were prescribed a standard combination [23] of (1) 2
antihypertensives (2 different kinds selected from thiazide diuretics, calcium channel blockers,
angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and beta-block-
ers) [24], (2) a statin, and (3) a low dose aspirin, unless contraindicated. Patients with only dia-
betes received the same pharmaceutical package but with only 1 antihypertensive, plus their
anti-diabetic medicines, if any. Patients already on other older antihypertensive medicines
were advised to switch to the recommended medicines in standardised packages. Patients who
had a history of, or showed signs of, gastrointestinal bleeding were not prescribed aspirin. Dur-
ing consultation, family doctors provided individualised health education focusing on smok-
ing cessation, salt reduction, and reduction of alcohol consumption depending on the patient’s
situation. A family treatment supporter was selected at the patient’s home to support him/her
taking medicines and adhering to lifestyle changes. At the facility level, we provided annual
training to all family doctors using our CVD risk management guidelines, which covered (1)
prescribing for primary prevention of CVD, (2) personalised advice for healthy lifestyle
changes, and (3) advice to improve adherence [16]. Township hospitals held monthly meetings
to discuss doctors’ experience of using the guidelines and chronic disease management
(Table 1).
Data collection
On enrolment, family doctors measured participants’ blood pressure using a standardised
mercury sphygmomanometer after 5 minutes of seated rest. They also measured their body
weight and height, and asked for details on their medication history. These measures were
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repeated on a quarterly basis when participants were followed up in township hospitals. All
information was recorded in an internet-based public health management information system.
The trial stopped 36 months (May 2017) after enrolment of the last participant based on our
protocol.
All acute severe CVD events were collected through Zhejiang CDC’s surveillance system
[25] based on the adapted WHO MONICA definitions [26] compatible with ICD-10 codes.
These included coronary heart disease (CHD) and stroke, where CHD includes acute myocar-
dial infarction, ischaemic cardiac arrest, and unclassifiable CHD deathsAU : unclassifiabledeathsðfromanycause?ÞseemsoverlybroadtobeasubcategoryofCHD:IfthisshouldinsteadbeunclassifiableCHDdeathsorunclassifiableCHDeventsorsomeotherterm; pleaseedit:, and stroke includ s
haemorrhagic stroke (e.g., subarachnoid and intracerebral), ischaemic stroke/infarction (e.g.,
thrombosis and embolism), and unclassifiable stroke [27]. We did not include minor CVD
events such as angina and transient ischaemic attacks because they are often unrecorded. To
be eligible as endpoints, all CVD events had to be verified from hospital records, and were
reviewed and verified by centres for disease control at the county and provincial levels. All
reported CVD events were then also been verified by primary care facilities through home vis-
its. The process was supervised under the Validation Committee in the Zhejiang CDC. We
previously reported on the data collection, reporting, and validation of the Zhejiang CDC’s
surveillance system [25]. In addition, family doctors asked participants if they had experienced
Table 1. Intervention strategies to reduce the risk of cardiovascular disease (CVD).
Target Intervention strategies in the intervention arm Usual care in the control arm
Family doctors Operational guidelines: The guidelines contained a definition of high
risk of CVD, workflow chart for patient management, how to diagnose
hypertension and type 2 diabetes, suggested prescriptions and CVD risk
management practices, lifestyle evaluation and recommendations,
treatment support, and managing the side effects of medicines. In
addition, we also incorporated elements of China’s national
hypertension and type 2 diabetes guidelines for township hospitals.
Training workshops: Training workshops were provided on an annual
basis by local senior doctors based on the operational guidelines,
including hypertension/diabetes management, prevention, and
communication skills, using lectures, health education videos, case
discussions, role plays, and question and answer sessions.
Monthly meetings in township hospitals for performance
monitoring: A senior doctor led the review of the implementation of
intervention strategies, and provided comments to related questions on
CVD risk management and treatment of patients by doctors.
Guidelines and training: National hypertension and type 2 diabetes
guidelines were available but were not referred to in practice because
the guidelines focus on tertiary care. No specific training/guidelines
were given on reducing CVD risks based on a holistic approach.
Training workshops: Routine annual training workshops on
hypertension and type 2 diabetes management were provided, but
there was no research-driven systematic training provided on CVD
risk management.
Monthly meetings: Routine monthly internal meetings were held, but





Recommended medicines: A combination of 2 antihypertensives, a
statin, and a low dose of aspirin were recommended to patients with
hypertension. One antihypertensive, a statin, and a low dose of aspirin
were recommended for patients with type 2 diabetes but not
hypertension. Anti-diabetic medicine or insulin was given for diabetic
patients if necessary.
Health education messages from family doctors during regular
follow-up consultations (from monthly to quarterly): In their
consultations, family doctors gave targeted health education messages
to participants based on their health conditions, e.g., smoking cessation
messages to smokers, and messages regarding the benefits of the
combined medicines to those who did not adhere to prescriptions.
Enhanced follow-up appointment: Participants attended follow-up
consultations in township hospitals at least quarterly with their family
doctors. Nurses communicated with participants monthly through
phone calls/SMS messages.
Treatment supporter: Family doctors or nurses helped to identify and
train a treatment supporter (normally a family member) who reminded
patients to take medicines, maintain a healthy lifestyle, and adhere to
their follow-up consultations.
Recommend medications and health education: Treatment and
lifestyle changes were offered according to existing knowledge and at
the individual clinician’s discretion, but based on either hypertension
or type 2 diabetes instead of a holistic approach for CVD prevention.
In practice, most doctors prescribed only 1 antihypertensive for
hypertensive patients, and no antihypertensive for diabetic patients.
Very few patients were given a statin or aspirin. Anti-diabetic
medicine or insulin was given for diabetic patients if necessary.
Existing general health education messages were provided.
Follow-up appointment: Patients with hypertension or type 2
diabetes were followed up at least quarterly by family doctors
according to national guidelines.
Treatment supporter: The option of a treatment supporter was not
provided.
Medicines Modern medicines were available in both the intervention and control arms, and their prices were the same in the 2 arms.
https://doi.org/10.1371/journal.pmed.1003694.t001
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any stroke or heart attack events that were diagnosed by hospitals at the 12th, 24th, and 36th
month following randomisation; if any, the CVD events were reported to the Validation Com-
mittee and then verified and included in the records. Participants were classified as lost to fol-
low-up if they could not be contacted after 3 attempts (via telephone, message, or home visit)
and their CVD status was unknown by the 36th month.
Outcomes
All outcomes were measured at the patient level. The primary outcome was the number of
severe CVD events recorded by Zhejiang’s CVD surveillance system [25]. We also collected
the following secondary outcomes: (1) AU : Ichangedthenumberingofthislistsothatthenumbereditemsallhaveparallelstructure:Thenumberingisnotreferencedinthemaintext; exceptforonereferencelaterinthisparagraph;whichisunaffectedbytherenumbering:mortality du to severe CVD event, (2) numb r of
CHD events, (3) mortality due to CHD event, (4) number of stroke events, (5) mortality due to
stroke, (6) time to the first reported severe CVD event, (7) time to mortality due to CVD, (8)
change in diastolic and systolic blood pressure (mm Hg) between baseline and 36 months, (9)
adherence to the final quarterly follow-up consultation at 36 months, and (10) self-reported
adherence at 36 months to 2 antihypertensive drugs for patients with hypertension or 1 antihy-
pertensive drug for patients with only diabetes, aspirin, and statin. We also recorded any
minor or serious adverse events. We added secondary outcomes 2–5 to identify any changes in
CVD subgroups. In subsequent papers, we will report our other protocol-defined secondary
outcomes from our panel data and cost-effectiveness analysis, which are based on different
datasets as per our protocol [16]. We also previously reported feasibility measures in our pro-
cess evaluation paper [28].
Statistical analysis
We calculated AU : Pleasecheckthattheeditstothesentence}Wecalculated:::}captureyourmeaning; particularlythewordingbasedonanassumed5%levelinthecontrolarm:Ifitisnotcorrect; pleaseeditasnecessary:the necessary sample siz as 32 clust rs per arm and 450 patients pe cluster, to
have 90% power to detect a 20% reduction in the severe CVD event incidence rate after 36
months, based on an assumed CVD event rate of 5% in the control arm and a coefficient of
variation of 0.15, with hypothesis testing using a 2-sided P value with a 5% threshold for statis-
tical significance.
We calculated the exact follow-up time for each participant until the end of the trial or
death. We estimated crude and covariate-adjusted (“adjusted”) estimates of the treatment
effect on all outcomes using generalised linear mixed models (GLMMs). To estimate the crude
treatment effect (as an incidence rate ratio [IRR]) on our primary outcome, we used a GLMM
with a fixed effect for treatment arm, a random intercept for cluster, and an “offset” variable
for the log of person follow-up time, which used a log-link with Poisson errors. To estimate
the adjusted treatment effect, we repeated the same model but included patient-level variables
as per table footnotes. We also estimated crude and adjusted treatment effects for all our sec-
ondary outcomes using a variety of mixed-effects models, with the same random and fixed
effects (unless stated: see relevant table footnotes) included. We employed GLMMs with Pois-
son errors and log-links (if no evidence of overdispersion) or GLMMs with negative binomial
distributions and log-links (with treatment effects estimated as IRRs) to analyse event and
mortality outcomes, Cox proportional hazard mixed-effects models (with treatment effects
estimated as HRs) for time to event outcomes, GLMMs with normal errors and identity links
(with treatment effects estimated as mean differences) for blood pressure outcomes, and
GLMMs with binomial errors and logistic links (with treatment effects estimated as odds ratios
[ORs]) for adherence and adverse event outcomes. The intra-cluster correlation coefficient for
the primary outcome was calculated by dividing the between-cluster variance by the total vari-
ance. The variance terms were estimated by fitting the relevant (Poisson/negative binomial)
unconditional mixed-effects model with a random intercept for cluster [29,30]. All 95%
PLOS MEDICINE Risk-based pharmaceutical and lifestyle interventions in rural China
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confidence intervals and P values for GLMMs were based on either the Wald statistic (non-
normal errors) or the t statistic (normal errors). We analysed all data using SAS statistical soft-
ware (PROC MIXED and PROC GLIMMIX functions). Where any patients were missing out-
comes or covariates in adjusted analyses, we excluded these patients and performed complete
case analyses. We also ran cluster-level analyses for all our outcomes, as reported in S1 Text.
Our primary AU : Pleasecheckthattheeditstothesentence}Ourprimaryanalysis:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:analysis was of the in ention-t -tr at (ITT) population and included all partic-
ipants within all clusters as originally recruited and randomised, including all participants who
left the trial after their first consultation or moved out of their cluster catchment area, and
those who were wrongly classified as eligible: They all remained in the province so their CVD
status was still tracked by the surveillance system. We also defined a “modified ITT” analysis
population, which included all clusters and patients as originally recruited and randomised
but excluding any patients with missing outcome or covariate data. We also repeated our anal-
yses for all outcomes reported here in a per-protocol analysis population using the same meth-
ods described above. This per-protocol analysis population included all clusters as originally
recruited and randomised, and across both arms it included all eligible patients except those
patients who left the trial within the first quarter or those who were wrongly recruited. In addi-
tion, in the intervention arm this population excluded patients who did not have at least 50%
adherence to their prescriptions across all their follow-up consultations. This included taking
recommended antihypertensives (specifically, patients with hypertension taking a standard
combination of 2 antihypertensives, and patients with diabetes only taking 1 antihypertensive)
and statins or aspirin. These per-protocol analyses were designed after the trial because we
observed a low rate of adherence to prescriptions, beyond what we expected.
We did a range of exploratory subgroup analyses of the primary outcome based on the pre-
randomisation baseline characteristics of diagnosis (hypertension or hypertension and diabe-
tes versus diabetes only), patient income level (<10,000 RMB [<US$1,644] versus�10,000
RMB [�US$1,644] per annum), AU : USdollarvaluesweregivenherefortheincomecategories; butRMBvaluesweregiveninthetableandfigurefootnotes:IaddedtheRMBvalueshere; andequatedthemwiththeUSvalues:Ifthisisnotcorrect; pleaseedit:and education (primary school or below versus high school or
above). In our analyses of secondary outcomes and in our per-protocol and subgroup analyses,
we did not adjust the P values or confidence intervals for multiple testing, and we treat the
results as exploratory.
Results
We randomised 34 township hospitals to the intervention arm and 33 township hospitals to
the control arm. Across all hospitals’ catchment areas, based on electronic health records, we
identified a total of 31,326 potentially eligible participants: 15,380 in the intervention arm and
15,946 in the control arm. At the recruitment stage (December 2013 to May 2014), 1,995 and
1,201 eligible participants declined to participate in the intervention and control arms, respec-
tively, resulting in recruitment of 13,385 (87%) and 14,745 (92%) participants in the interven-
tion and control arms, respectively (Fig 1).
As shown in Table 2, participants in the 2 arms were similar with respect to baseline charac-
teristics. The mean age was 64 years, 51% were women, 90% were farmers, and 77% had a pri-
mary education or below. The median annual per capita income was US$1,424, reflecting the
poor and rural setting. Of all participants, 64% were diagnosed with hypertension with or with-
out diabetes, and 36% were diagnosed with diabetes only. Following their first consultation,
1,144 and 1,694 participants in the intervention and control arms, respectively, chose to stop par-
ticipating, and 76 and 83 participants in the intervention and control arms, respectively, were
found to have pre-existing CVD (and therefore ineligible), but all were included in the ITT analy-
sis population. During the follow-up there were 366 and 483 all-cause mortalities, and 135 and
194 participants moved out of their cluster catchment areas, in the intervention and control
PLOS MEDICINE Risk-based pharmaceutical and lifestyle interventions in rural China
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arms, respectively (Fig 1). All clusters and participants were successfully followed up based on
electronic medical records and/or CVD events reported via family doctors, allowing us to have
complete data for the primary and secondary outcomes for the ITT population. However, there
were some missing data for the adherence and blood pressure outcomes, and for the covariates
in adjusted analyses. Missing case details are provided in the footnotes of the results tables.
Our interventions did not have a statistically significant effect on the primary outcome.
Among all participants, 762 and 874 severe CVD events were reported in the intervention and
Fig 1. Trial profile. aIneligible patients included 2,419,058 who didn’t meet the eligibility criteria (aged 50–74 years, with a calculated 10-year CVD
risk� 20% and having hypertension, or diagnosed with type 2 diabetes); 222 who had mental diseases; 492 who had cancers; 2,076 who had pre-
existing acute coronary heart disease or had experienced a stroke according to heath records; 293 whose diastolic blood pressure was<60 mm Hg;
16,562 who were out of town for more than 3 months or were non-locals/urban residents; and 1,155 who couldn’t take the recommended medicines
due to other severe diseases. bPatients whose records of acute cardiovascular diseases or death could not be obtained at the end of the 36-month
follow-up period were categorised as lost to follow-up. cPatients who died (intervention = 366, control = 483), moved out of cluster catchment areas
(intervention = 135, control = 194), were subsequently found to have pre-existing acute cardiovascular diseases not identified through initial health
records (intervention = 76, control = 83), or subsequently decided to leave the trial within the first quarter of the follow-up period
(intervention = 1,144, control = 1,694) are all included in the main (covariate unadjusted) intention-to-treat (ITT) analyses. dPatients excluded from
the per-protocol analysis: (1) AU : PleasecheckthattheeditstoFig1; footnoted; exclusioncriterion1arecorrect:Ifnot; pleaseedit:patients in the intervention gr up who did not r port taking both suggested hypertensive medicines and a statin/
aspirin for more than half of the follow-up period before the occurrence of acute cardiovascular disease, if they had an occurrence, or until the end
of follow-up, if they did not (n = 11,523); (2) patients who were subsequently found to have pre-existing acute cardiovascular diseases not identified
through initial health records (intervention = 76, control = 83); and (3) patients who subsequently decide to leave the trial within the first quarter of
the follow-up period (intervention = 1,144, control = 1,694).
https://doi.org/10.1371/journal.pmed.1003694.g001
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control arms, respectively. The majority (99.4%) of CVD events were collected through Zhe-
jiang’s CVD surveillance system, while 4 and 5 CVD events from the intervention and control
arms, respectively, were collected via family doctors at their consultations. The observed inci-
dence rate for severe CVD events was 1.92 and 2.01 per 100 person-years in the intervention
and control arms respectively, and the crude IRR was 0.90 (95% CI: 0.74, 1.08; P = 0.259;
Table 3). The primary outcome’s IRR was not substantially altered when adjusting for covari-
ates (Table 3). There was no significant treatment effect on any of the secondary event, mortal-
ity, or time to event outcomes, including CVD mortality (Tables 3 and 4). The results from
our adjusted analyses were consistent with the crude results for all secondary outcomes (Tables
3 and 4). The cluster-level analyses of both primary and secondary outcomes produced results
consistent with those of the patient-level analyses (Tables A–C in S1 Text).
Our per-protocol population included just 642 participants in the intervention arm and
excluded 2 clusters in the intervention arm that had no remaining participants, while retaining
12,968 patients and all clusters in the control arm. There were no significant differences
between the 2 arms regarding severe CVD events (1.58 versus 1.94 per 100 person-years in the
intervention and control groups, respectively; crude IRR = 0.81 [95% CI: 0.55, 1.20;
Table 2. Characteristics of the 28,130 participants in the trial.
Patient characteristics Intervention group (n = 13,385) Control group (n = 14,745) Total (n = 28,130)
Number of clusters 34 33 67
Age (years), mean (SD) 64.3 (6.3) 64.2 (6.1) 64.3 (6.1)
Sex, n (%)
Male 6,443 (48.1%) 7,316 (49.6%) 13,759 (48.9%)
Female 6,942 (51.9%) 7,429 (50.4%) 14,371 (51.1%)
Body mass index (kg/m2), mean (SD) 24.0 (3.0) 23.9 (2.9) 23.9 (2.9)
Occupation, n (%)
Farmer 11,735 (89.9%) 12,960 (90.2%) 24,695 (90.0%)
Worker 205 (1.6%) 181 (1.3%) 386 (1.4%)
Technician 37 (0.3%) 55 (0.4%) 92 (0.3%)
Administrative staff 18 (0.1%) 8 (0.1%) 26 (0.1%)
Service worker 58 (0.4%) 56 (0.4%) 114 (0.4%)
Personal business 197 (1.5%) 165 (1.2%) 362 (1.3%)
Retired 105 (0.8%) 169 (1.2%) 274 (1.0%)
Other 702 (5.4%) 778 (5.4%) 1,480 (5.4%)
Educational level, n (%)
Primary school or below 10,356 (77.7%) 11,070 (75.4%) 21,426 (76.5%)
High school 2,691 (20.2%) 3,234 (22.0%) 5,925 (21.1%)
College or above 290 (2.1%) 382 (2.6%) 672 (2.4%)
Marital status, n (%)
Married 11,813 (95.4%) 13,109 (95.6%) 24,922 (95.5%)
Single, divorced, or widowed 566 (4.6%) 610 (4.4%) 1,176 (4.5%)
Annual per capita income (US dollars), median (IQR) 1,424 (712, 1,994)a 1,424 (712, 2,374)a 1,424 (712, 2,136)a
Diagnosis, n (%)
Hypertension with/without type 2 diabetes 8,800 (65.7%) 9,224 (62.6%) 18,024 (64.1%)
Type 2 diabetes without hypertension 4,585 (34.2%) 5,521 (37.4%) 10,106 (35.9%)
10-year CVD risk in patients with hypertension, median (IQR) 26.5% (23.0%, 30.8%) 26.3% (22.9%, 30.8%) 26.4% (22.9%, 30.8%)
aThe recommended package of medicines cost US$35–US$44 per month in the local setting, i.e., US$420–US$528 per year.
https://doi.org/10.1371/journal.pmed.1003694.t002
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P = 0.298]). When analysing the per-protocol population there were also no significant results
in our secondary outcomes of mortality and events (Tables D–F in S1 Text).
Table 3. Comparison of primary and secondary outcomes for disease event rates between the intervention and control arms (individual-level data analyses).
Outcome Intervention Control Crude IRR (95% CI)b P valueb Adjusted IRR (95% CI)c P valuec
N (%)a Event rate N (%)a Event rate
CVD eventd 762 (5.69%) 1.92 874 (5.93%) 2.01 0.90 (0.74 to 1.08) 0.259 0.87 (0.73 to 1.05) 0.148
CVD mortality 165 (1.23%) 0.42 185 (1.25%) 0.42 0.91 (0.69 to 1.21) 0.516 0.90 (0.68 to 1.18) 0.455
CHD event 92 (0.69%) 0.23 120 (0.81%) 0.28 0.84 (0.63 to 1.11) 0.217 0.86 (0.65 to 1.14) 0.290
CHD mortality 43 (0.32%) 0.11 55 (0.37%) 0.13 0.80 (0.46 to 1.37) 0.410 0.73 (0.39 to 1.37) 0.331
Stroke event 659 (4.92%) 1.66 738 (5.01%) 1.69 0.91 (0.75 to 1.11) 0.359 0.88 (0.73 to 1.07) 0.200
Stroke mortality 122 (0.91%) 0.31 132 (0.90%) 0.30 0.99 (0.75 to 1.30) 0.932 0.99 (0.77 to 1.28) 0.937
CHD, coronary heart disease; CVD, cardiovascular disease; IRR, incidence rate ratio. Intervention, n = 13,385; control, n = 14,745. The total person-years of follow-up
were 39,657 and 43,557 for the intervention group and control group, respectively.
aIndividual-level summary statistics: N is the number of events; percent is the total number of events/total number of individuals (per arm). Event rate is per 100 person-
years. For all disease event outcomes (as opposed to disease mortality outcomes), individuals may experience >1 event, and so the N (%) statistics are based on the
occurrence/non-occurrence of the event per person only.
bThe intervention minus control crude IRRs were obtained via a Poisson mixed-effects model (primary outcome) or a Poisson or negative binomial mixed-effects model
(secondary outcomes: depending on the level of dispersion) with a single fixed effect of treatment arm and a random intercept for cluster. The 95% CIs and P values
were calculated based on the Wald statistic. In all crude analyses there were no missing patients.
cThe intervention minus control adjusted IRRs were obtained via a Poisson mixed-effects model (primary outcome) or a Poisson or negative binomial mixed-effects
model (secondary outcomes: depending on the level of dispersion) with fixed effects for treatment arm, patient age, sex, body mass index, occupation (farmer or non-
farmer), educational level (primary school or below, or high school or above), marital status (married or non-married), income (less than 10,000 RMB or 10,000 RMB or
above), and diagnosis (hypertension without type 2 diabetes, type 2 diabetes without hypertension, or hypertension with type 2 diabetes), and a random intercept for
cluster. The 95% CIs and P values were calculated based on the Wald statistic. In all adjusted analyses, 1,112 (8.3%) and 1,432 (9.7%) patients in the intervention and
control arms, respectively, were excluded due to missing outcome or covariate data.
dOnly 14 and 19 patients in the intervention and control arms, respectively, reported a second severe CVD event, and none reported more than 2 severe CVD events.
The intra-cluster correlation coefficient for the primary CVD event outcome was 0.024, and was calculated by dividing the between-cluster variance by the total
variance. The variance terms were estimated by fitting the relevant (Poisson or negative binomial) unconditional mixed-effects model with only a random intercept for
cluster.
https://doi.org/10.1371/journal.pmed.1003694.t003
Table 4. Comparison of time to first CVD event and time to CVD mortality outcomes between the intervention and control arms (individual-level data analyses)AU : InTable4; headrow : IchangedthefootnoteforthefirstPvaluecolumnfromctob:Ifthisisnotcorrect; pleaseedit:.
Outcome Mean (SD) number of daysa Crude HR (95% CI)b P valueb Adjusted HR (95% CI)c P valuec
Intervention Control
Time to the first CVD event 554.2 (311.4) 554.8 (314.8) 0.87 (0.72 to 1.05) 0.140 0.86 (0.72 to 1.03) 0.108
Time to CVD mortality 614.8 (314.8) 627.4 (307.2) 0.92 (0.69 to 1.22) 0.543 0.91 (0.69 to 1.19) 0.478
CVD, cardiovascular disease; HR, hazard ratio. Intervention, n = 13,385; control, n = 14,745.
aIndividual-level summary data are presented as mean (SD) number of days until the outcome, excluding censored outcomes.
bThe intervention minus control crude HRs were obtained using a mixed-effects Cox proportional hazard model with a single fixed effect of treatment arm and a
random intercept for cluster. The 95% CIs and P values were calculated based on the Wald statistic. In both crude analyses there were no missing patients.
cThe intervention minus control adjusted HRs were obtained using a mixed-effects Cox proportional hazard model with fixed effects for treatment arm, patient age, sex,
body mass index, occupation (farmer or non-farmer), educational level (primary school or below, or high school or above), marital status (married or non-married),
income (less than 10,000 RMB or 10,000 RMB or above), and diagnosis (hypertension without type 2 diabetes, type 2 diabetes without hypertension, or hypertension
with type 2 diabetes), and a random intercept for cluster. The 95% CIs and P values were calculated based on the Wald statistic. In the adjusted analysis of the time to
first CVD event outcome, 1,153 (8.6%) and 1,470 (10.0%) patients in the intervention and control arms, respectively, were excluded due to missing covariate data, and in
the adjusted analysis of the time to CVD mortality outcome, 1,644 (12.3%) and 2,037 (13.8%) patients in the intervention and control arms, respectively, were excluded
due to missing covariate data.
https://doi.org/10.1371/journal.pmed.1003694.t004
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We did AU : Pleasecheckthattheeditstothesentences}Wedidobserve:::}andInourper   protocolanalyses:::captureyourmeaning:Thekeyedit; asintheAbstract;waschangingreductionstodifferences; toclarifythatthevaluesrepresentthedifferenceinchangebetweeninterventionandcontrolarms; notthechangeitself ðfrombaselineto36monthsÞwithinarms:Iftheseeditsarenotcorrect; pleaseprovidecorrectwording:observe significan crud differences in th intervention arm compared to the con-
trol arm in the change from baseline to 36 months regarding systolic blood pressure (−1.44
mm Hg [95% CI: −2.26, −0.62; P< 0.001]) and diastolic blood pressure (−1.29 mm Hg [95%
CI: −1.77, −0.80; P< 0.001]), with similar adjusted results (Table 5). In our per-protocol analy-
ses we observed a similarly sized significant difference in diastolic blood pressure change
(−1.25 mm Hg [95% CI: −2.02, −0.49; P = 0.001]), but a non-significant difference in systolic
blood pressure change (−0.64 mm Hg [95% CI: −1.88, −0.60; P = 0.315]; Table G in S1 Text).
Fig 2 illustrates that adherence to recurring booked quarterly consultations remained high
in both arms throughout the trial, only appearing to decline slightly from 4 months until 36
months in both arms. Correspondingly, there was no significant difference between arms in
patients’ adherence to their final quarterly consultations (adjusted OR [AOR] = 1.44 [95% CI:
0.88, 2.36; P = 0.144]). In total, 84.9% (11,359) of patients in the intervention arm had a treat-
ment supporter, compared with only 0.4% (63) of patients in the control arm (AOR = 159.32,
[95% CI: 124.53, 203.81; P< 0.001]). In most cases, treatment supporters were patients’
spouses and children. Among patients with hypertension, either alone or with diabetes, as
shown in Fig 3A and 3B, only 22.5% reported adherence to 2 antihypertensive drugs at base-
line in both arms. This then steadily increased to 37.2% at 36 months in the intervention arm
compared to 16.8% in the control arm (AOR = 4.75 [95% CI: 3.82, 5.91; P< 0.001]). In the
intervention arm, patients reported significant improvement in adherence to aspirin (1% at
baseline and 16.7% at 36 months) and statins (0.4% at baseline and 8% at 36 months), com-
pared to consistently low levels of adherence reported in the control arm (aspirin, 1% at base-
line and 1.7% at 36 months; AOR = 12.1 [95% CI: 7.69, 18.9; P< 0.001]; and statin, 0.4% at
baseline and 0.8% at 36 months; AOR = 9.69 [95% CI: 5.65, 16.6; P< 0.001]). Among patients
with only diabetes (Fig 3C and 3D), we did not identify a significant difference between the 2
arms in adherence to 1 antihypertensive at 36 months (AOR = 1.31 [95% CI: 0.93, 1.84;
P = 0.13]). Their adherence to aspirin was around 1% at baseline in both arms, but this
increased substantially in the intervention arm (to 8.9%) but not in the control arm (1.1%),
Table 5. Comparison of systolic and diastolic blood pressure outcomes between intervention and control arms (individual-level data analyses).
Outcome Mean (SD) blood pressure (mm
Hg)
Crude mean difference (95% CI)a P valuea Adjusted mean difference (95% CI)b P valueb
Intervention Control
Systolic blood pressure
Baseline 136.2 (11.7) 135.9 (11.4)
Endline 132.4 (9.34) 133.4 (9.71) −1.44 (−2.26 to −0.62) <0.001 −1.50 (−2.30 to −0.70) <0.001
Diastolic blood pressure
Baseline 81.7 (6.81) 81.8 (6.67)
Endline 79.5 (6.31) 80.6 (6.30) −1.29 (−1.77 to −0.80) <0.001 −1.31 (−1.79 to −0.83) <0.001
Intervention, n = 13,385; control, n = 14,745.
aThe intervention minus control crude mean endline differences were obtained via a linear mixed-effects model with a single fixed effect of treatment arm and a random
intercept for cluster. The 95% CI and P values were calculated based on the t statistic. In both crude analyses there were no missing patients.
bThe intervention minus control adjusted mean endline differences were obtained via a linear mixed-effects model with fixed effects for treatment arm, patient age, sex,
body mass index, occupation (farmer or non-farmer), educational level (primary school or below, or high school or above), marital status (married or non-married),
income (less than 10,000 RMB or 10,000 RMB or above), and diagnosis (hypertension without type 2 diabetes, type 2 diabetes without hypertension, hypertension with
type 2 diabetes), and a random intercept for cluster. The 95% CI and P values were calculated based on the t statistic. In the adjusted analysis of the systolic blood
pressure outcome, 2,624 (19.6%) and 3,339 (22.6%) patients in the intervention and control arms, respectively, were excluded due to missing covariate or outcome data,
and in the adjusted analysis of the diastolic blood pressure outcome 2,620 (19.6%) and 3,338 (22.6%) patients in the intervention and control arms, respectively, were
excluded due to missing covariate or outcome data.
https://doi.org/10.1371/journal.pmed.1003694.t005
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reflecting a significantly higher level of adherence in the intervention arm at 36 months
(AOR = 9.09 [95% CI: 5.44, 15.2; P< 0.001]). For these patients, there was a similar pattern
observed for statin adherence, with near 0% adherence at baseline in both arms but 6.1%
adherence in the intervention arm, compared to 0.4% in the control arm, at 36 months
(AOR = 12.8 [95% CI: 6.68, 24.5; P< 0.001]).
We analysed patients’ self-reported adherence (yes/no) to at least 1 or 2 antihypertensive
medicines, aspirin, and/or a statin at 36 months of follow-up via mixed-effects logistic regres-
sion models, with fixed effects for treatment arm, patient age, sex, body mass index, occupa-
tion (farmer or non-farmer), educational level (primary school or below, or high school or
above), marital status (married or non-married), income (less than 10,000 RMB or 10,000
RMB or above), and diagnosis (hypertension without type 2 diabetes, type 2 diabetes without
hypertension, hypertension with type 2 diabetes), and a random intercept for cluster. In the
subgroup of patients with hypertension (intervention n = 8,800, control n = 9,224), self-
reported adherence to at least 2 antihypertensive drugs, aspirin, and/or a statin at 36 months
was significantly higher in intervention arm patients compared to control arm patients (AOR
for self-reported adherence to at least 2 antihypertensive medicines at 36 months = 4.75 [95%
CI: 3.82, 5.91; P< 0.001]; AOR for self-reported adherence to aspirin at 36 months = 12.1
[95% CI: 7.69, 18.9; P< 0.001]; AOR for self-reported adherence to a statin at 36 months = 9.69
[95% CI: 5.65, 16.6; P< 0.001]). In all these subgroup analyses, 851 (9.7%) and 1,094 (11.9%)
patients in the intervention and control arms, respectively, were excluded due to missing
covariate or outcome data. In the subgroup of patients with type 2 diabetes only (intervention
n = 4,585, control n = 5,521), self-reported adherence to at least 1 antihypertensive medicine at
Fig 2. Adherence to booked quarterly consultations. Adherence to booked consultations is calculated as the
proportion of patients in each arm who responded to their quarterly (i.e., every 3 months) follow-up clinical
consultations with health workers within each 3-month follow-up period. A mixed-effects logistic regression analysis
of patients’ adherence (yes/no) to their final quarterly booked consultation—with fixed effects for treatment arm,
patient age, sex, body mass index, occupation (farmer or non-farmer), educational level (primary school or below, or
high school or above), marital status (married or non-married), income (less than 10,000 RMB or 10,000 RMB or
above), and diagnosis (hypertension without type 2 diabetes, type 2 diabetes without hypertension, hypertension with
type 2 diabetes), and a random intercept for cluster—demonstrated no significant difference between treatment arms
(intervention versus control adjusted odds ratio = 1.44 [95% CI: 0.88, 2.36; P = 0.144]). This analysis excluded 1,112
(8.3%) and 1,432 (9.7%) patients from the intention-to-treat population intervention (n = 13,385) and control
(n = 14,745) arms, respectively, due to missing covariate or outcome data.
https://doi.org/10.1371/journal.pmed.1003694.g002
PLOS MEDICINE Risk-based pharmaceutical and lifestyle interventions in rural China
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003694 July 1, 2021 13 / 21
36 months was not significantly higher in intervention arm patients compared to control arm
patients (AOR for self-reported adherence to at least 1 antihypertensive medicine = 1.31 [95%
CI: 0.93, 1.84; P = 0.13]), but self-reported adherence to aspirin and/or a statin at 36 months
was significantly higher in intervention arm patients compared to control arm patients (AOR
for aspirin = 9.09 [95% CI: 5.44, 15.2; P< 0.001]; AOR for statin = 12.8 [95% CI: 6.68, 24.5; P
< 0.001]). In all these subgroup analyses, 1,494 (32.6%) and 1,999 (36.2%) patients were
excluded from the intervention and control arms, respectively, due to missing covariate or out-
come data.
A total of 148 (1.1%) and 185 (1.3%) patients reported minor adverse events in the interven-
tion and control arms, respectively (AOR = 0.927 [95% CI: 0.514, 1.673; P = 0.802]). Of 333
reported adverse events, 134 (40.2%) were gastrointestinal discomfort, 73 (21.9%) were dizzi-
ness, 50 (15.0%) were hypodynamia, 35 (10.5%) were undefined bleeding, and 41 (12.4%) were
other unclassified conditions. No significant difference AU : Pleasecheckthattheeditstothesentence}Nosignficantdifference:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:was identifi d for any cat gory of
adverse event (Table I in S1 Text). We did not identify any serious adverse events that required
emergency medical attention.
Fig 3. Self-reported adherence to medicines. (A and B) Self-reported adherence to medicines among patients with hypertension or hypertension and type 2 diabetes in
the (A) intervention and (B) control groups. (C and D) Self-reported adherence to medicines among patients with type 2 diabetes only in the (C) intervention and (D)
control groups.
https://doi.org/10.1371/journal.pmed.1003694.g003
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Discussion
To our knowledge, this is the first large-scale, pragmatic, cluster randomised controlled trial
with long-term follow-up that investigates the effect of a comprehensive CVD-risk-based pre-
vention strategy on CVD events. We did not observe a statistically significant difference
regarding the primary outcome measure of severe CVD events within 36 months. Nor did we
identify a statistically significant effect on the primary outcome in our per-protocol analyses,
where we only included intervention arm participants who reported at least 50% adherence to
recommended prescriptions. However, only 4.6% of patients were retained in the intervention
arm per-protocol population, despite the relatively low adherence threshold for inclusion.
Therefore, along with the limitations of per-protocol analyses, to robustly understand the
actual treatment effect in this context, as opposed to the effect of just providing the treatment
option, would clearly require further study. There was a AU : Pleasecheckthattheeditstothesentence}Therewasasignificant:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:significant diff rence in the secondary
outcomes of systolic and diastolic blood pressure change from baseline to follow-up that
favoured the intervention over the control treatment, but it was small. Related to this, we also
observed statistically significant and clinically moderate to large improvements in patient-
reported adherence to 2 antihypertensives, aspirin, and statins, albeit the overall adherence
rates to all medicines were low. We found no other statistically significant intervention effects
for any of our other secondary outcomes within the crude or adjusted ITT or per-protocol
population analyses.
Several health system issues may limit the effectiveness of such interventions. First, low
health insurance coverage for medicines and high out-of-pocket payments may discourage
patients from taking recommended medicines. Though our intervention substantially
improved adherence rates (i.e., to 37% for recommended antihypertensives, 17% for aspirin,
and 6% for statins in the intervention arm), the rates were nevertheless far lower than those in
trials providing free medicines. For example, the PolyIran trial [6] achieved 81% adherence,
and an atorvastatin trial [31] had 85% adherence. Based on strategies of motivating commu-
nity health workers and providing free medicines, the HOPE4 trial reported 84% adherence to
antihypertensives and statin [11]. Our adherence rates mimic conditions in real-life settings,
where less than 50% of patients with hypertension regularly take antihypertensives [32]. In our
setting, the recommended package of medicines cost US$35–US$44 per month, with partici-
pants having a median annual per capita income of US$1,424. Our process evaluation revealed
that affordability of medicines was a major challenge due to low health insurance coverage for
outpatient costs. In practice, most patients paid their outpatient medicines out of pocket
[28,33]. China extended universal health coverage to everyone in 2009, which reduced the pro-
portion of out-of-pocket health expenditure, but not the absolute level [34]. In addition, outpa-
tient costs, as often seen in primary care, are proportionally much less covered than inpatient
costs. This problem is exacerbated as cheaper generic medicines often become unavailable in
township hospitals because the companies supplying them cannot make profits under current
bidding regulations [28]. This affordability challenge has created a health equity crisis in pri-
mary care in China, wherein the poorest quintile of patients with diabetes experience the high-
est burden of catastrophic health expenditure [35]. Second, our participants were mainly older
people who had previously been treated for hypertension or diabetes, and they were commonly
reluctant to change from their existing combination tablet, which contained antihypertensive
and traditional Chinese medicine, to multiple pills, which represented a higher pill burden
[15]. Polypill is not available in our setting. Third, the low level of trust that patients have in
family doctors in China, as we identified in our sites [28] and another province [36], may have
also contributed to the low adherence to prescriptions and healthy lifestyle advice.
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We designed this pragmatic trial to be embedded in real-life primary care practice so as to
better inform health policy. We minimised participant eligibility criteria to reflect the general
population of patients with hypertension and/or diabetes as managed under primary care. Our
data collection, based on the province-wide CVD surveillance system, enabled us to collect pri-
mary and most secondary endpoints from all participants, including patients who moved out
of our study sites and those who agreed to participate but soon left the trial. We were therefore
able to conduct true ITT analyses without imputation, which is not possible in many trials.
The pharmaceutical and healthy lifestyle interventions were designed to fit into the job
descriptions of family doctors under the new payment and incentive system of China’s health
reform. Our studies showed that the interventions were feasible for health providers [15] and
patients [17].
Our study has several limitations. First, at recruitment all participants were verbally
informed that they had 20% or greater risk AU : Ichangedover20%riskto20%orgreaterrisk; tomatchthecutoffusedelsewhereinthepaper:Ifthisisnotcorrect i:e:; ifparticipantsweretoldover20%riskregardlessoftheactualcutoff pleaseeditasnecessary:of developing CVD in the next 10 years, and that
they needed to adopt activities to reduce this risk, such as treating their hypertension and/or
diabetes and making general healthy lifestyle changes. They all had their blood pressure mea-
sured and participated in a questionnaire survey. These activities can be seen as an interven-
tion itself as some patients in the control arm may have modified their medicines and/or
lifestyles. This potentially reduced the difference in primary and secondary outcomes observed
between in the intervention and control arms. Second, we employed the Asian equation to cal-
culate the 10-year CVD risk of participants, but the Asian equation does not consider any
comorbidities or complications that may contribute to a higher risk of CVD. However, AU : Pleasecheckthattheeditstothesentence}However; :::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:we
included all patients with diabetes, who were more likely to have complications than patients
with hypertension. Third, there was no blinding for healthcare providers or patients, although
the outcome analyses were blinded. However, given the largely null results, there was no evi-
dence of the typical inflation of effect sizes seen due to lack of blinding. Fourth, we could not
collect baseline information for the 3,196 (10%) eligible patients who declined participation
based on ethical considerations. Therefore, we could not fully assess how comparable the trial
cohort was to the wider target population. Fifth, our 36-month follow-up period is shorter
than that of other trials employing CVD events as the primary endpoint, which normally use
60 months. However, given the health system limitations identified here, a longer follow-up
period is unlikely to generate substantially better impact on CVD events. Sixth,AU : Pleasecheckthattheeditstothesentence}Sixth:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:we wer not
able to collect information regarding lipid profiles, blood glucose, and healthy lifestyle behav-
iours for all participants due to the concern that too many data collection activities could alter
routine services. We collected the information in a panel of participants and will report these
results elsewhere. Seventh, recall and reporting biases may exist because we collected self-
reported adherence to medicines. Electronic pill boxes were not available during our study,
and even if available, they may alter provider and patient behaviour. Lastly, any attempt at
robustly estimating the likely effect of the treatment if adhered to was not possible due to the
very small proportion of individuals who adhered at even a modest rate in the intervention
arm.
Our intervention’s lack of effectiveness on CVD events is consistent with results from trials
examining CVD-risk-based management interventions in primary care settings in HICs
[8,37–39]. One of the major limitations of these previous trials is that their interventions were
all light-touch, focusing on providing healthy lifestyle advice, with only 1 suggesting antihyper-
tensive treatment. Unlike in these trials, we observed improved adherence to medications and
significant but small reductions in blood pressure. There were another 2 trials from LMICs
that implemented comprehensive pharmaceutical and lifestyle interventions among popula-
tions with high CVD risk [10,11]. Both achieved reductions in blood pressure, and one in
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CVD risk, but the trials were not designed to test effects on CVD events, they had a shorter
duration, and their sustainability was unclear.
CVD-risk-based pharmaceutical and healthy lifestyle management remains a popular pol-
icy for primary prevention of CVD as shown in WHO recommendations [1] and certain
national guidelines [40,41]. Our study, along with other studies from HICs [37–39], showed
that interventions that reduce CVD risks at the population level would be unlikely to have an
impact unless structural health system factors such as the availability of essential medicines are
addressed first. This calls for more implementation research to examine how interventions can
work in real-world settings. The context of the health system, as revealed in our study, deter-
mines the success of implementation. Health system factors at the policy, facility, and individ-
ual level need to be considered in future research. At the policy level, improved financing of
primary care is required to ensure patients have adequate access to family doctor services and
essential medicines. Free distribution of essential medicines, as shown in Ontario, Canada
[42], improved treatment adherence, and would be expected to reduce CVD risk factorsAU : IchangedwouldreduceCVDriskfactorstowouldbeexpectedtoreduceCVDriskfactors:Ifthisisnotcorrect; pleaseedit:,
which in return would substantially reduce societal costs associated with poor outcomes in
managing diabetes and hypertension in the long run [43]. At the facility level, risk-based man-
agement guidelines need to be made compatible with local primary care delivery to accommo-
date regular patient follow-ups and personalised health education [44]. At the individual level,
patients have to be constantly supported and encouraged for positive changes. This requires
AU : Pleasecheckthattheeditstothesentence}Thisrequires:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:involvement of ommunity-based h alth workers, patient eng gem nt and empowerment for
disease self-management, shared decision-making, and use of telemedicine and apps in the
post-coronavirus-pandemic era [2].
In conclusion, our study showed that our comprehensive package of risk-based pharmaceu-
tical and health lifestyle interventions for patients with hypertension and diabetes improved
patient adherence to essential medicines and reduced patient blood pressure, but importantly
it did not reduce severe CVD events. Revisiting key health system components, such as
improving universal health coverage for essential medicines, is crucial in designing future trials
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